Malignant Head and Neck Neoplasm clinical trials

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Head and neck cancer study for older adults

This trial tests a combination of chemotherapy and immunotherapy followed by radiation for older adults with head and neck cancer. It aims to see if this approach is safe and effective for people aged 65 and older.

Study of lower radiation and chemo for head and neck cancer

This study tests whether giving lower doses of radiation and chemotherapy is safe and effective for people with certain head and neck cancers. It aims to reduce side effects while keeping the treatment successful.

3D-printed tongue stents during head and neck radiation

This Phase 2 study tests whether customized 3D-printed stents can be used safely during head and neck radiotherapy. If you’re having radiation (with or without chemotherapy), the stent may help make treatment easier and more precise, potentially improving the experience and outcomes.

Decitabine plus standard therapy for HPV-negative head and neck cancer

This trial tests whether adding the drug decitabine to standard treatment (surgery and possibly radiation) can help people with a type of head and neck cancer not caused by HPV. You would receive decitabine before surgery, and then continue with standard care after.

Blood test study for early cancer detection in patients

This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.

Simple blood, urine, and saliva test to find cancer early

This study tests a new way to find cancer by looking at DNA in blood, urine, and saliva. It may help detect cancer earlier and monitor how well treatment works.

Blood DNA test in newly diagnosed head and neck cancer

This study looks at “circulating tumor DNA” (tumor DNA found in blood) in people with newly diagnosed, locally advanced head and neck squamous cell cancer. Researchers want to see how the blood DNA levels relate to the cancer and how it may guide treatment after surgery.

Gene-edited immune cells for advanced melanoma or solid tumors

This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.

Test of an EGFR-targeting drug for advanced solid cancers

This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.

Genetic testing study for cancer patients in different ethnic groups

This study looks at cancer-related inherited gene changes using blood samples. It may help patients and doctors understand cancer risk and guide treatment planning, especially across different ethnic communities.

Study drug IACS-6274 tested for advanced solid tumors

This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.

Radiation plan that tries to protect swallowing organs

This Phase 3 study compares a standard radiation approach versus a modified approach designed to spare key swallowing and aspiration (choking) related areas and one salivary gland. It may help reduce treatment side effects that affect swallowing and quality of life for certain head and neck cancer patients.

Pembrolizumab with chemotherapy for returning or spread head cancer

This Phase 2 study tests pembrolizumab (an immunotherapy) plus chemotherapy to treat head and neck cancer that has come back or spread. You might be eligible if standard local treatments won’t be curative and your tumor can be measured on scans.

Early trial for advanced cancers using HTL0039732

This is a Phase 1/2 study testing how well HTL0039732 works and is tolerated in people with advanced solid tumors that have not responded to standard treatments. It may help by offering a new treatment option and learning which cancer types and body markers respond best.

Home cancer treatment vs clinic treatment for advanced cancer

This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.

Oropharynx cancer biomarker study

This study looks at certain markers (called p16 and HPV) in tumor samples to better understand oropharynx cancer. It may help doctors learn more about the disease and guide future treatments.

Comparing treatment approaches for head and neck cancer after radiation

This study looks back at different treatment approaches for people with head and neck cancer who received radiation therapy at the S. Orsola Polyclinic. It aims to understand which strategies worked best, and may help improve future care.

Finding the right dose of a new combo for head and neck cancer

This trial tests a new three-drug combination for advanced head and neck cancer that cannot be cured by local treatments. It aims to find the best dose of a targeted therapy called Zanzalintinib when given with two standard immunotherapy and targeted drugs.

Drug combination for returning head and neck cancer

This trial tests a combination of three drugs—methotrexate, erlotinib, and celecoxib—for people whose head and neck cancer has come back or spread. It is designed for patients in the rural Midwest who have already had or chosen not to have standard first treatment.

Molecular testing of head and neck tumors

This study looks at head and neck tumors using molecular and genetic tests. It may help doctors learn more about what drives different tumors and how they might respond to treatment, using biopsy or stored tumor tissue.

Study follow-up after proton radiation treatment

This study collects information about both short-term and long-term side effects in people who receive proton radiation. It may help doctors better understand what happens to normal tissues over time and improve follow-up care.

How activity level and daily function relate to cancer survival

This study looks at how physical activity (movement during the day) and a clinician-rated “day-to-day function” score relate to overall survival in people with certain cancers. It may help doctors understand who benefits most from activity-focused care and better monitoring.

Morning vs. afternoon immunotherapy for advanced solid tumors

This trial compares giving immunotherapy in the morning versus the afternoon to see if timing affects how well it works. It is for people with certain types of advanced or metastatic solid tumors who have not had this treatment before.